Poly (ADP-ribose) polymerase - Revision history

Michal Harel at 09:35, 18 January 2024

Michal Harel — Thu, 18 Jan 2024 09:35:45 GMT

←Older revision		Revision as of 09:35, 18 January 2024
Line 17:		Line 17:
	PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.		PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.

-	See also [[Olaparib]].
	== 3D Structures of Poly (ADP-ribose) polymerase ==		== 3D Structures of Poly (ADP-ribose) polymerase ==
	[[Poly(ADP-ribose) polymerase 3D structures]]		[[Poly(ADP-ribose) polymerase 3D structures]]

Michal Harel at 09:34, 18 January 2024

Michal Harel — Thu, 18 Jan 2024 09:34:56 GMT

←Older revision		Revision as of 09:34, 18 January 2024
Line 12:		Line 12:

	== Relevance ==		== Relevance ==
-	PARP inhibitors are investigated as mono therapy against breast cancer<ref>PMID:22106552</ref>. [[~~Olparib~~]] is a PARP inhibitor used as medication against ovarian cancer. Over-expression of PARP-14 rescues myeloma cells from apoptosis.	+	PARP inhibitors are investigated as mono therapy against breast cancer<ref>PMID:22106552</ref>. [[Olaparib]] is a PARP inhibitor used as medication against ovarian cancer. Over-expression of PARP-14 rescues myeloma cells from apoptosis.

	== Structural highlights ==		== Structural highlights ==

Michal Harel at 09:34, 18 January 2024

Michal Harel — Thu, 18 Jan 2024 09:34:33 GMT

←Older revision		Revision as of 09:34, 18 January 2024
Line 12:		Line 12:

	== Relevance ==		== Relevance ==
-	PARP inhibitors are investigated as mono therapy against breast cancer<ref>PMID:22106552</ref>. Over-expression of PARP-14 rescues myeloma cells from apoptosis.	+	PARP inhibitors are investigated as mono therapy against breast cancer<ref>PMID:22106552</ref>. [[Olparib]] is a PARP inhibitor used as medication against ovarian cancer. Over-expression of PARP-14 rescues myeloma cells from apoptosis.

	== Structural highlights ==		== Structural highlights ==

Alexander Berchansky at 06:18, 19 October 2023

Alexander Berchansky — Thu, 19 Oct 2023 06:18:45 GMT

←Older revision		Revision as of 06:18, 19 October 2023
Line 17:		Line 17:
	PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.		PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.

		+	See also [[Olaparib]].
	== 3D Structures of Poly (ADP-ribose) polymerase ==		== 3D Structures of Poly (ADP-ribose) polymerase ==
	[[Poly(ADP-ribose) polymerase 3D structures]]		[[Poly(ADP-ribose) polymerase 3D structures]]

Michal Harel at 08:47, 25 November 2019

Michal Harel — Mon, 25 Nov 2019 08:47:46 GMT

←Older revision		Revision as of 08:47, 25 November 2019
Line 21:		Line 21:

	</StructureSection>		</StructureSection>
-	== 3D Structures of Poly (ADP-ribose) polymerase ==

-	Updated on {{REVISIONDAY2}}-{{MONTHNAME\|{{REVISIONMONTH}}}}-{{REVISIONYEAR}}
-	{{#tree:id=OrganizedByTopic\|openlevels=0\|
-
-	*Poly (ADP-ribose) polymerase 1; Domains – zinc finger 1 2-96; zinc finger 2 105-206; zinc finger 3 216-366; BRCT 389-487; WGR 517-642; ART 788-1012; catalytic 662-1101
-
-	**[[3od8]], [[3oda]] – hPARP 1 zinc finger 1 + DNA – human<br />
-	**[[2dmj]], [[1v9x]] - hPARP 1 zinc finger 1 - NMR<br />
-	**[[3odc]], [[3ode]] - hPARP 1 zinc finger 2 + DNA<br />
-	**[[2cs2]], [[2l30]], [[2l31]] - hPARP 1 zinc finger 2 - NMR<br />
-	**[[2riq]] - hPARP-1 zinc finger 3<br />
-	**[[2jvn]] – hPARP 1 zinc finger 3 – NMR<br />
-	**[[4av1]] - hPARP-1 zinc fingers 1,2+ DNA<br />
-	**[[2n8a]] - hPARP-1 zinc fingers 1,2+ DNA – NMR<br />
-	**[[2cr9]] - hPARP 1 WGR domain – NMR<br />
-	**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />
-	**[[2rcw]], [[4pjt]] - hPARP 1 α-helical and catalytic domain + inhibitor<br />
-	**[[3gjw]] – hPARP 1 α-helical and catalytic domain (mutant) + inhibitor<br />
-	**[[2cok]] – hPARP-1 C terminal (mutant) – NMR<br />
-	**[[4dqy]] - hPARP-1 zinc fingers 1,3 and WGR domain + DNA<br />
-	**[[2le0]] - PARP-1 BRCT domain – rat - NMR<br />
-	**[[3u9h]] – hPARP-1 catalytic domain + nicotinamide<br />
-	**[[6bhv]] – hPARP 1 catalytic domain + NAD homolog<br />
-	**[[1uk0]], [[1uk1]], [[4gv7]], [[1wok]], [[4hhy]], [[4hhz]], [[2rd6]], [[4r5w]], [[4r6e]], [[4rv6]], [[4und]], [[4uxb]], [[4zzz]], [[5a00]], [[5ds3]], [[5ha9]], [[5xsu]], [[5xst]], [[5xsr]] – hPARP-1 catalytic domain + inhibitor<br />
-	**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]], [[5kpn]], [[5kpo]], [[5kpp]], [[5kpq]], [[5wrq]], [[5wry]], [[5wrz]], [[5ws0]], [[5ws1]], [[5wtc]], [[6ghk]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />
-	**[[6nrf]], [[6nrg]], [[6nrh]], [[6nri]], [[6nrj]] – hPARP 1 ART domain + inhibitor<br />
-	**[[4xhu]] – hPARP 1 catalytic domain + protein homeless homolog<br />
-	**[[4opx]], [[4oqa]], [[4oqb]] – hPARP-1 zinc fingers 1,2,3, WGR and catalytic domain + DNA<br />
-	**[[6i8m]], [[6imt]] – cPARP-1 catalytic domain + inhibitor – chicken<br />
-
-	*Poly (ADP-ribose) polymerase 2
-
-	**[[3kjd]], [[3kcz]], [[4tvj]], [[4zzx]], [[4zzy]], [[5dsy]] - hPARP 2 catalytic domain + inhibitor<br />
-	**[[4pjv]] - hPARP 2 α helical and catalytic domain + inhibitor<br />
-	**[[6f1k]], [[6f5b]], [[6f5f]] - hPARP 2 WGR domain + DNA<br />
-	**[[5d5k]] - hPARP 2 residues 1-78 + importin subunit -1 <br />
-	**[[1gs0]] - mPARP 2 catalytic domain - mouse
-
-	*Poly (ADP-ribose) polymerase 3
-
-	**[[2eoc]] – hPARP-3 WGR domain – NMR<br />
-	**[[3c49]], [[3c4h]], [[3ce0]], [[3fhb]], [[4gv0]], [[4gv2]], [[4gv4]], [[4l6z]], [[4l70]], [[4l7l]], [[4l7n]] [[4l7o]], [[4l7p]], [[4l7r]], [[4l7u]] - hPARP-3 catalytic domain + inhibitor
-
-	*Poly (ADP-ribose) polymerase 9
-
-	**[[5ail]] – hPARP-9 macrodomain 2<br />
-
-	*Poly (ADP-ribose) polymerase 10
-
-	**[[5lx6]] - hPARP 10 catalytic domain + inhibitor<br />
-	**[[3hkv]] - hPARP 10 catalytic domain (mutant) + inhibitor<br />
-	**[[6fxi]] - hPARP-10 catalytic domain + aminobenzamide<br />
-	**[[2dhx]] - hPARP 10 RRM domain
-
-	*Poly (ADP-ribose) polymerase 11
-
-	**[[2dk6]] - hPARP 11 WWE domain – NMR<br />
-
-	*Poly (ADP-ribose) polymerase 12
-
-	**[[2pqf]] - hPARP-12 catalytic domain + inhibitor
-
-	*Poly (ADP-ribose) polymerase 14; Domains – WWE 139-224; macro 1 708-898; macro 2 918-1115; macro 3 1208-1388; catalytic 1611-1801
-
-	**[[3goy]], [[3se2]], [[3smi]], [[3smj]], [[4f1l]], [[4f1q]], [[4py4]], [[5lxp]], [[5lyh]], [[5nqe]], [[5v7t]], [[5v7w]], [[6g0w]], [[6fym]], [[6fzm]] - hPARP 14 catalytic domain + inhibitor<br />
-	**[[3q6z]] - hPARP-14 macro domain 1+ ADPR<br />
-	**[[3q71]] - hPARP-14 macro domain 2+ ADPR<br />
-	**[[5o2d]] - hPARP-14 macro domain 2 (mutant) + inhibitor<br />
-	**[[3vfq]], [[4d86]] - hPARP-14 macro domain 1+2 + ADPR<br />
-	**[[4abk]] - hPARP-14 macro domain 3+ ADPR<br />
-	**[[4abl]] - hPARP-14 macro domain 1<br />
-	**[[1x4r]] - mPARP-14 WWE domain – NMR<br />
-
-	*Poly (ADP-ribose) polymerase 15
-
-	**[[3blj]] - hPARP-15 catalytic domain<br />
-	**[[4f0e]] - hPARP-15 catalytic domain + ligand<br />
-	**[[3gey]] - hPARP-15 catalytic domain + inhibitor<br />
-	**[[6ek3]] - hPARP-15 catalytic domain (mutant) + inhibitor<br />
-	**[[3v2b]] – hPARP-15 macro domain 2 + ADP<br />
-
-	*Poly (ADP-ribose) polymerase 16 residues 5-279
-
-	**[[4f0d]] - hPARP-16 + aminobenzamide<br />
-	**[[6hxr]] - hPARP-16 + inhibitor<br />
-	**[[6hxs]] - hPARP-16 + CABRA-NAD<br />
-
-	*Poly (ADP-ribose) polymerase
-
-	**[[1a26]] – cPARP catalytic domain +carba-NAD – chicken<br />
-	**[[2paw]] - cPARP catalytic domain<br />
-	**[[2pax]], [[4pax]], [[3pax]], [[1pax]], [[1efy]] - cPARP catalytic domain + inhibitor<br />
-	**[[5ngo]] – AtPARP Rcd1 PARP domain residues 269-460 – ''Arabidopsis thaliana''<br />
-	**[[5n9q]] – AtPARP Rcd1 residues 468-567 <br />
-
-	*Tankyrases 1 (SAM domain 1018-1093; catalytic domain 1093-1325)
-
-	**[[5jti]], [[5ju5]], [[5kni]] - hTank 1 SAM domain<br />
-	**[[2rf5]] - hTank 1 catalytic domain (mutant)<br />
-	**[[3udd]], [[3uh2]], [[3uh4]], [[4dvi]], [[4i9i]], [[4k4e]], [[4k4f]], [[4krs]], [[4li6]], [[4li7]], [[4li8]], [[4msg]], [[4msk]], [[4mt9]], [[4n3r]], [[4n4v]], [[4oa7]], [[4w5s]], [[4w6e]], [[4tor]], [[4u6a]], [[4uuh]], [[4uw1]], [[5ebt]], [[5ece]], [[6qxu]] - hTank 1 catalytic domain + inhibitor<br />
-	**[[4tos]], [[5ety]] - hTank 1 catalytic domain (mutant) + inhibitor<br />
-	**[[5gp7]] - hTank 1 residues 799-957 + USP25<br />
-	**[[5jhq]] - hTank 1 residues 174-649 + peptide<br />
-
-	*Tankyrase 2 or PARP 5b (SAM domain 867-940; catalytic domain 946-1113; C-terminal domain 1114-1162)
-
-	**[[5jrt]] - hTank 2 SAM domain<br />
-	**[[3twq]] - hTank 2 residues 484-655<br />
-	**[[3twr]], [[3tws]], [[3twt]], [[3twu]], [[3twv]], [[3tww]], [[3twx]], [[4z68]], [[5bxo]], [[5bxu]] - hTank 2 residues 484-655 + peptide substrate<br />
-	**[[3kr7]] - hTank 2 catalytic domain<br />
-	**[[4hki]] - hTank 2 catalytic + C terminal domains<br />
-	**[[3mhk]], [[3mhj]], [[3p0n]], [[3p0p]], [[3p0q]], [[3kr8]], [[3kr8]], [[3u9y]], [[3ua9]], [[3w51]], [[4avu]], [[4avw]], [[4bfp]], [[4bj9]], [[4bjb]], [[4bjc]], [[4bs4]], [[4bu3]], [[4bu5]], [[4bu6]], [[4bu7]], [[4bu8]], [[4bu9]], [[4bua]], [[4bud]], [[4bue]], [[4buf]], [[4bui]], [[4bus]], [[4but]], [[4buu]], [[4buv]], [[4buw]], [[4bux]], [[4buy]], [[4hyf]], [[4iue]], [[4j1z]], [[4j21]], [[4j22]], [[4j3l]], [[4j3m]], [[4m7b]], [[4pml]], [[4pnl]], [[4pnm]], [[4pnn]], [[4pnq]], [[4pnr]], [[4pns]], [[4pnt]], [[4tju]], [[4tjw]], [[4tjy]], [[4tk0]], [[4tk5]], [[4tkf]], [[4tkg]], [[4tki]], [[5aku]], [[5akw]], [[5al1]], [[5al2]], [[5al3]], [[5al4]], [[5al5]], [[4ufu]], [[4uhg]], [[4ui3]], [[4ui4]], [[4ui5]], [[4ui6]], [[4ui7]], [[4ui8]], [[4uvl]], [[4uvn]], [[4uvo]], [[4uvp]], [[4uvs]], [[4uvt]], [[4uvu]], [[4uvv]], [[4uvw]], [[4uvx]], [[4uvy]], [[4uvz]], [[4ux4]], [[4w5i]], [[5adq]], [[5adr]], [[5ads]], [[5adt]], [[5aeh]], [[5owt]], [[5ows]] - hTank 2 catalytic domain+ inhibitor<br />
-	**[[4hkk]], [[4hkn]], [[4hl5]], [[4hlf]], [[4hlg]], [[4hlh]], [[4hlk]], [[4hlm]], [[4hmh]], [[4kzl]], [[4kzq]], [[4kzu]], [[4l09]], [[4l0b]], [[4l0i]], [[4l0s]], [[4l0t]], [[4l0v]], [[4l10]], [[4l2f]], [[4l2g]], [[4l2k]], [[4l31]], [[4l32]], [[4l33]], [[4l34]], [[5c5p]], [[5c5q]], [[5c5r]], [[5dcz]], [[5fpf]], [[5fpg]], [[5nxe]], [[5nwg]], [[5nwd]], [[5nwc]], [[5nwb]] [[5nvh]], [[5nvf]], [[5nve]], [[5nvc]], [[5nut]], [[5nt4]], [[5nt0]], [[5nsx]], [[5nsp]], [[5nob]], [[4ufy]] - hTank 2 catalytic and C terminal domains + inhibitor<br />
-	}}
	== References ==		== References ==
	<references/>		<references/>
	[[Category:Topic Page]]		[[Category:Topic Page]]

Michal Harel at 08:46, 25 November 2019

Michal Harel — Mon, 25 Nov 2019 08:46:48 GMT

Alexander Berchansky at 13:24, 12 August 2019

Alexander Berchansky — Mon, 12 Aug 2019 13:24:55 GMT

←Older revision		Revision as of 13:24, 12 August 2019
Line 15:		Line 15:

	== Structural highlights ==		== Structural highlights ==
-	PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>3 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/4'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.	+	PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.
	</StructureSection>		</StructureSection>
	== 3D Structures of Poly (ADP-ribose) polymerase ==		== 3D Structures of Poly (ADP-ribose) polymerase ==

Michal Harel at 08:54, 26 August 2018

Michal Harel — Sun, 26 Aug 2018 08:54:12 GMT

Michal Harel at 23:08, 21 October 2017

Michal Harel — Sat, 21 Oct 2017 23:08:43 GMT

←Older revision		Revision as of 23:08, 21 October 2017
Line 1:		Line 1:
-	<StructureSection load='4hhy' size='350' side='right' caption='Human ~~poly (ADP-ribose) polymerase 1~~ complex with ~~DNA~~, ~~carboxyamide inhibitor and Zn~~+~~2 ion~~ (~~grey~~) (PDB entry [[4hhy]])' scene=''>	+
		+	<StructureSection load='4hhy' size='350' side='right' caption='Human glycosylated plasminogen complex with acetate, bicarbonate, K+ (purple) and Cl- (green) ions (PDB entry [[4hhy]])' scene=''>
	__TOC__		__TOC__
	== Function ==		== Function ==

Michal Harel at 23:06, 21 October 2017

Michal Harel — Sat, 21 Oct 2017 23:06:24 GMT

←Older revision		Revision as of 23:06, 21 October 2017
Line 1:		Line 1:
-	<StructureSection load='~~4opx~~' size='350' side='right' caption='Human poly (ADP-ribose) polymerase 1 complex with DNA, carboxyamide inhibitor and Zn+2 ion (grey) (PDB entry [[~~4opx~~]])' scene=''>	+	<StructureSection load='4hhy' size='350' side='right' caption='Human poly (ADP-ribose) polymerase 1 complex with DNA, carboxyamide inhibitor and Zn+2 ion (grey) (PDB entry [[4hhy]])' scene=''>
	__TOC__		__TOC__
	== Function ==		== Function ==

←Older revision		Revision as of 08:46, 25 November 2019
Line 16:		Line 16:
	== Structural highlights ==		== Structural highlights ==
	PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.		PARP1 is composed of 3 domains. Among them are the N terminal DNA-binding domain which contains <scene name='43/439963/Cv/3'>5 zinc fingers (residues 1-97, 105-206, 207-366)</scene>. The auto modification (AD) domain which contains a breast cancer 1 protein (BRCT) C-terminus domain (residues 386-485) and a WGR domain (rich in Trp, Gly and Arg) (residues 517-642). The C terminal domain which includes the catalytic domain (or PARP domain) (residues 662-1011)<ref>PMID:19372272</ref>. <scene name='43/439963/Cv/6'>A potential drug binds at the active site pocket</scene><ref>PMID:24922587</ref>.
		+
		+	== 3D Structures of Poly (ADP-ribose) polymerase ==
		+	[[Poly(ADP-ribose) polymerase 3D structures]]
		+
	</StructureSection>		</StructureSection>
	== 3D Structures of Poly (ADP-ribose) polymerase ==		== 3D Structures of Poly (ADP-ribose) polymerase ==
Line 22:		Line 26:
	{{#tree:id=OrganizedByTopic\|openlevels=0\|		{{#tree:id=OrganizedByTopic\|openlevels=0\|

-	*Poly (ADP-ribose) polymerase 1; Domains – zinc finger 1 2-96; zinc finger 2 105-206; zinc finger 3 216-366; BRCT 389-487; WGR 517-642; catalytic 662-1101	+	*Poly (ADP-ribose) polymerase 1; Domains – zinc finger 1 2-96; zinc finger 2 105-206; zinc finger 3 216-366; BRCT 389-487; WGR 517-642; ART 788-1012; catalytic 662-1101

	**[[3od8]], [[3oda]] – hPARP 1 zinc finger 1 + DNA – human<br />		**[[3od8]], [[3oda]] – hPARP 1 zinc finger 1 + DNA – human<br />
Line 42:		Line 46:
	**[[6bhv]] – hPARP 1 catalytic domain + NAD homolog<br />		**[[6bhv]] – hPARP 1 catalytic domain + NAD homolog<br />
	**[[1uk0]], [[1uk1]], [[4gv7]], [[1wok]], [[4hhy]], [[4hhz]], [[2rd6]], [[4r5w]], [[4r6e]], [[4rv6]], [[4und]], [[4uxb]], [[4zzz]], [[5a00]], [[5ds3]], [[5ha9]], [[5xsu]], [[5xst]], [[5xsr]] – hPARP-1 catalytic domain + inhibitor<br />		**[[1uk0]], [[1uk1]], [[4gv7]], [[1wok]], [[4hhy]], [[4hhz]], [[2rd6]], [[4r5w]], [[4r6e]], [[4rv6]], [[4und]], [[4uxb]], [[4zzz]], [[5a00]], [[5ds3]], [[5ha9]], [[5xsu]], [[5xst]], [[5xsr]] – hPARP-1 catalytic domain + inhibitor<br />
-	**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]], [[5kpn]], [[5kpo]], [[5kpp]], [[5kpq]], [[5wrq]], [[5wry]], [[5wrz]], [[5ws0]], [[5ws1]], [[5wtc]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />	+	**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]], [[5kpn]], [[5kpo]], [[5kpp]], [[5kpq]], [[5wrq]], [[5wry]], [[5wrz]], [[5ws0]], [[5ws1]], [[5wtc]], [[6ghk]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />
		+	**[[6nrf]], [[6nrg]], [[6nrh]], [[6nri]], [[6nrj]] – hPARP 1 ART domain + inhibitor<br />
	**[[4xhu]] – hPARP 1 catalytic domain + protein homeless homolog<br />		**[[4xhu]] – hPARP 1 catalytic domain + protein homeless homolog<br />
	**[[4opx]], [[4oqa]], [[4oqb]] – hPARP-1 zinc fingers 1,2,3, WGR and catalytic domain + DNA<br />		**[[4opx]], [[4oqa]], [[4oqb]] – hPARP-1 zinc fingers 1,2,3, WGR and catalytic domain + DNA<br />
		+	**[[6i8m]], [[6imt]] – cPARP-1 catalytic domain + inhibitor – chicken<br />

	*Poly (ADP-ribose) polymerase 2		*Poly (ADP-ribose) polymerase 2
Line 50:		Line 56:
	**[[3kjd]], [[3kcz]], [[4tvj]], [[4zzx]], [[4zzy]], [[5dsy]] - hPARP 2 catalytic domain + inhibitor<br />		**[[3kjd]], [[3kcz]], [[4tvj]], [[4zzx]], [[4zzy]], [[5dsy]] - hPARP 2 catalytic domain + inhibitor<br />
	**[[4pjv]] - hPARP 2 α helical and catalytic domain + inhibitor<br />		**[[4pjv]] - hPARP 2 α helical and catalytic domain + inhibitor<br />
		+	**[[6f1k]], [[6f5b]], [[6f5f]] - hPARP 2 WGR domain + DNA<br />
	**[[5d5k]] - hPARP 2 residues 1-78 + importin subunit -1 <br />		**[[5d5k]] - hPARP 2 residues 1-78 + importin subunit -1 <br />
	**[[1gs0]] - mPARP 2 catalytic domain - mouse		**[[1gs0]] - mPARP 2 catalytic domain - mouse
Line 66:		Line 73:
	**[[5lx6]] - hPARP 10 catalytic domain + inhibitor<br />		**[[5lx6]] - hPARP 10 catalytic domain + inhibitor<br />
	**[[3hkv]] - hPARP 10 catalytic domain (mutant) + inhibitor<br />		**[[3hkv]] - hPARP 10 catalytic domain (mutant) + inhibitor<br />
		+	**[[6fxi]] - hPARP-10 catalytic domain + aminobenzamide<br />
	**[[2dhx]] - hPARP 10 RRM domain		**[[2dhx]] - hPARP 10 RRM domain

Line 78:		Line 86:
	*Poly (ADP-ribose) polymerase 14; Domains – WWE 139-224; macro 1 708-898; macro 2 918-1115; macro 3 1208-1388; catalytic 1611-1801		*Poly (ADP-ribose) polymerase 14; Domains – WWE 139-224; macro 1 708-898; macro 2 918-1115; macro 3 1208-1388; catalytic 1611-1801

-	**[[3goy]], [[3se2]], [[3smi]], [[3smj]], [[4f1l]], [[4f1q]], [[4py4]], [[5lxp]], [[5lyh]], [[5nqe]], [[5v7t]], [[5v7w]], [[6g0w]] - hPARP 14 catalytic domain + inhibitor<br />	+	**[[3goy]], [[3se2]], [[3smi]], [[3smj]], [[4f1l]], [[4f1q]], [[4py4]], [[5lxp]], [[5lyh]], [[5nqe]], [[5v7t]], [[5v7w]], [[6g0w]], [[6fym]], [[6fzm]] - hPARP 14 catalytic domain + inhibitor<br />
	**[[3q6z]] - hPARP-14 macro domain 1+ ADPR<br />		**[[3q6z]] - hPARP-14 macro domain 1+ ADPR<br />
	**[[3q71]] - hPARP-14 macro domain 2+ ADPR<br />		**[[3q71]] - hPARP-14 macro domain 2+ ADPR<br />
Line 95:		Line 103:
	**[[3v2b]] – hPARP-15 macro domain 2 + ADP<br />		**[[3v2b]] – hPARP-15 macro domain 2 + ADP<br />

-	*Poly (ADP-ribose) polymerase 16	+	*Poly (ADP-ribose) polymerase 16 residues 5-279

-	**[[4f0d]] - hPARP-16 + aminobenzamide	+	**[[4f0d]] - hPARP-16 + aminobenzamide<br />
		+	**[[6hxr]] - hPARP-16 + inhibitor<br />
		+	**[[6hxs]] - hPARP-16 + CABRA-NAD<br />

	*Poly (ADP-ribose) polymerase		*Poly (ADP-ribose) polymerase
Line 111:		Line 121:
	**[[5jti]], [[5ju5]], [[5kni]] - hTank 1 SAM domain<br />		**[[5jti]], [[5ju5]], [[5kni]] - hTank 1 SAM domain<br />
	**[[2rf5]] - hTank 1 catalytic domain (mutant)<br />		**[[2rf5]] - hTank 1 catalytic domain (mutant)<br />
-	**[[3udd]], [[3uh2]], [[3uh4]], [[4dvi]], [[4i9i]], [[4k4e]], [[4k4f]], [[4krs]], [[4li6]], [[4li7]], [[4li8]], [[4msg]], [[4msk]], [[4mt9]], [[4n3r]], [[4n4v]], [[4oa7]], [[4w5s]], [[4w6e]], [[4tor]], [[4u6a]], [[4uuh]], [[4uw1]], [[5ebt]], [[5ece]] - hTank 1 catalytic domain + inhibitor<br />	+	**[[3udd]], [[3uh2]], [[3uh4]], [[4dvi]], [[4i9i]], [[4k4e]], [[4k4f]], [[4krs]], [[4li6]], [[4li7]], [[4li8]], [[4msg]], [[4msk]], [[4mt9]], [[4n3r]], [[4n4v]], [[4oa7]], [[4w5s]], [[4w6e]], [[4tor]], [[4u6a]], [[4uuh]], [[4uw1]], [[5ebt]], [[5ece]], [[6qxu]] - hTank 1 catalytic domain + inhibitor<br />
	**[[4tos]], [[5ety]] - hTank 1 catalytic domain (mutant) + inhibitor<br />		**[[4tos]], [[5ety]] - hTank 1 catalytic domain (mutant) + inhibitor<br />
	**[[5gp7]] - hTank 1 residues 799-957 + USP25<br />		**[[5gp7]] - hTank 1 residues 799-957 + USP25<br />

←Older revision		Revision as of 08:54, 26 August 2018
Line 1:		Line 1:
-
	<StructureSection load='4hhy' size='350' side='right' caption='Human glycosylated plasminogen complex with acetate, bicarbonate, K+ (purple) and Cl- (green) ions (PDB entry [[4hhy]])' scene=''>		<StructureSection load='4hhy' size='350' side='right' caption='Human glycosylated plasminogen complex with acetate, bicarbonate, K+ (purple) and Cl- (green) ions (PDB entry [[4hhy]])' scene=''>
	__TOC__		__TOC__
Line 23:		Line 22:
	{{#tree:id=OrganizedByTopic\|openlevels=0\|		{{#tree:id=OrganizedByTopic\|openlevels=0\|

-	*Poly (ADP-ribose) polymerase 1	+	*Poly (ADP-ribose) polymerase 1; Domains – zinc finger 1 2-96; zinc finger 2 105-206; zinc finger 3 216-366; BRCT 389-487; WGR 517-642; catalytic 662-1101

	**[[3od8]], [[3oda]] – hPARP 1 zinc finger 1 + DNA – human<br />		**[[3od8]], [[3oda]] – hPARP 1 zinc finger 1 + DNA – human<br />
Line 41:		Line 40:
	**[[2le0]] - PARP-1 BRCT domain – rat - NMR<br />		**[[2le0]] - PARP-1 BRCT domain – rat - NMR<br />
	**[[3u9h]] – hPARP-1 catalytic domain + nicotinamide<br />		**[[3u9h]] – hPARP-1 catalytic domain + nicotinamide<br />
-	**[[1uk0]], [[1uk1]], [[4gv7]], [[1wok]], [[4hhy]], [[4hhz]], [[2rd6]], [[4r5w]], [[4r6e]], [[4rv6]], [[4und]], [[4uxb]], [[4zzz]], [[5a00]], [[5ds3]], [[5ha9]] – hPARP-1 catalytic domain + inhibitor<br />	+	**[[6bhv]] – hPARP 1 catalytic domain + NAD homolog<br />
		+	**[[1uk0]], [[1uk1]], [[4gv7]], [[1wok]], [[4hhy]], [[4hhz]], [[2rd6]], [[4r5w]], [[4r6e]], [[4rv6]], [[4und]], [[4uxb]], [[4zzz]], [[5a00]], [[5ds3]], [[5ha9]], [[5xsu]], [[5xst]], [[5xsr]] – hPARP-1 catalytic domain + inhibitor<br />
	**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]], [[5kpn]], [[5kpo]], [[5kpp]], [[5kpq]], [[5wrq]], [[5wry]], [[5wrz]], [[5ws0]], [[5ws1]], [[5wtc]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />		**[[3l3l]], [[3l3m]], [[3gn7]], [[4l6s]], [[5kpn]], [[5kpo]], [[5kpp]], [[5kpq]], [[5wrq]], [[5wry]], [[5wrz]], [[5ws0]], [[5ws1]], [[5wtc]] – hPARP 1 catalytic domain (mutant) + inhibitor<br />
	**[[4xhu]] – hPARP 1 catalytic domain + protein homeless homolog<br />		**[[4xhu]] – hPARP 1 catalytic domain + protein homeless homolog<br />
Line 76:		Line 76:
	**[[2pqf]] - hPARP-12 catalytic domain + inhibitor		**[[2pqf]] - hPARP-12 catalytic domain + inhibitor

-	*Poly (ADP-ribose) polymerase 14	+	*Poly (ADP-ribose) polymerase 14; Domains – WWE 139-224; macro 1 708-898; macro 2 918-1115; macro 3 1208-1388; catalytic 1611-1801

-	**[[3goy]], [[3se2]], [[3smi]], [[3smj]], [[4f1l]], [[4f1q]], [[4py4]], [[5lxp]], [[5lyh]], [[5nqe]], [[5v7t]], [[5v7w]] - hPARP 14 catalytic domain + inhibitor<br />	+	**[[3goy]], [[3se2]], [[3smi]], [[3smj]], [[4f1l]], [[4f1q]], [[4py4]], [[5lxp]], [[5lyh]], [[5nqe]], [[5v7t]], [[5v7w]], [[6g0w]] - hPARP 14 catalytic domain + inhibitor<br />
	**[[3q6z]] - hPARP-14 macro domain 1+ ADPR<br />		**[[3q6z]] - hPARP-14 macro domain 1+ ADPR<br />
	**[[3q71]] - hPARP-14 macro domain 2+ ADPR<br />		**[[3q71]] - hPARP-14 macro domain 2+ ADPR<br />
		+	**[[5o2d]] - hPARP-14 macro domain 2 (mutant) + inhibitor<br />
	**[[3vfq]], [[4d86]] - hPARP-14 macro domain 1+2 + ADPR<br />		**[[3vfq]], [[4d86]] - hPARP-14 macro domain 1+2 + ADPR<br />
	**[[4abk]] - hPARP-14 macro domain 3+ ADPR<br />		**[[4abk]] - hPARP-14 macro domain 3+ ADPR<br />
Line 91:		Line 92:
	**[[4f0e]] - hPARP-15 catalytic domain + ligand<br />		**[[4f0e]] - hPARP-15 catalytic domain + ligand<br />
	**[[3gey]] - hPARP-15 catalytic domain + inhibitor<br />		**[[3gey]] - hPARP-15 catalytic domain + inhibitor<br />
		+	**[[6ek3]] - hPARP-15 catalytic domain (mutant) + inhibitor<br />
	**[[3v2b]] – hPARP-15 macro domain 2 + ADP<br />		**[[3v2b]] – hPARP-15 macro domain 2 + ADP<br />

Line 97:		Line 99:
	**[[4f0d]] - hPARP-16 + aminobenzamide		**[[4f0d]] - hPARP-16 + aminobenzamide

-	*Poly (ADP-ribose) polymerase ~~- chicken~~	+	*Poly (ADP-ribose) polymerase

	**[[1a26]] – cPARP catalytic domain +carba-NAD – chicken<br />		**[[1a26]] – cPARP catalytic domain +carba-NAD – chicken<br />
	**[[2paw]] - cPARP catalytic domain<br />		**[[2paw]] - cPARP catalytic domain<br />
	**[[2pax]], [[4pax]], [[3pax]], [[1pax]], [[1efy]] - cPARP catalytic domain + inhibitor<br />		**[[2pax]], [[4pax]], [[3pax]], [[1pax]], [[1efy]] - cPARP catalytic domain + inhibitor<br />
		+	**[[5ngo]] – AtPARP Rcd1 PARP domain residues 269-460 – ''Arabidopsis thaliana''<br />
		+	**[[5n9q]] – AtPARP Rcd1 residues 468-567 <br />

	*Tankyrases 1 (SAM domain 1018-1093; catalytic domain 1093-1325)		*Tankyrases 1 (SAM domain 1018-1093; catalytic domain 1093-1325)
Line 112:		Line 116:
	**[[5jhq]] - hTank 1 residues 174-649 + peptide<br />		**[[5jhq]] - hTank 1 residues 174-649 + peptide<br />

-	*Tankyrase 2 (SAM domain 867-940; catalytic domain 946-1113; C-terminal domain 1114-1162)	+	*Tankyrase 2 or PARP 5b (SAM domain 867-940; catalytic domain 946-1113; C-terminal domain 1114-1162)

	**[[5jrt]] - hTank 2 SAM domain<br />		**[[5jrt]] - hTank 2 SAM domain<br />
Line 119:		Line 123:
	**[[3kr7]] - hTank 2 catalytic domain<br />		**[[3kr7]] - hTank 2 catalytic domain<br />
	**[[4hki]] - hTank 2 catalytic + C terminal domains<br />		**[[4hki]] - hTank 2 catalytic + C terminal domains<br />
-	**[[3mhk]], [[3mhj]], [[3p0n]], [[3p0p]], [[3p0q]], [[3kr8]], [[3kr8]], [[3u9y]], [[3ua9]], [[3w51]], [[4avu]], [[4avw]], [[4bfp]], [[4bj9]], [[4bjb]], [[4bjc]], [[4bs4]], [[4bu3]], [[4bu5]], [[4bu6]], [[4bu7]], [[4bu8]], [[4bu9]], [[4bua]], [[4bud]], [[4bue]], [[4buf]], [[4bui]], [[4bus]], [[4but]], [[4buu]], [[4buv]], [[4buw]], [[4bux]], [[4buy]], [[4hyf]], [[4iue]], [[4j1z]], [[4j21]], [[4j22]], [[4j3l]], [[4j3m]], [[4m7b]], [[4pml]], [[4pnl]], [[4pnm]], [[4pnn]], [[4pnq]], [[4pnr]], [[4pns]], [[4pnt]], [[4tju]], [[4tjw]], [[4tjy]], [[4tk0]], [[4tk5]], [[4tkf]], [[4tkg]], [[4tki]], [[5aku]], [[5akw]], [[5al1]], [[5al2]], [[5al3]], [[5al4]], [[5al5]], [[4ufu]], [[4uhg]], [[4ui3]], [[4ui4]], [[4ui5]], [[4ui6]], [[4ui7]], [[4ui8]], [[4uvl]], [[4uvn]], [[4uvo]], [[4uvp]], [[4uvs]], [[4uvt]], [[4uvu]], [[4uvv]], [[4uvw]], [[4uvx]], [[4uvy]], [[4uvz]], [[4ux4]], [[4w5i]], [[5adq]], [[5adr]], [[5ads]], [[5adt]], [[5aeh]] - hTank 2 catalytic domain+ inhibitor<br />	+	**[[3mhk]], [[3mhj]], [[3p0n]], [[3p0p]], [[3p0q]], [[3kr8]], [[3kr8]], [[3u9y]], [[3ua9]], [[3w51]], [[4avu]], [[4avw]], [[4bfp]], [[4bj9]], [[4bjb]], [[4bjc]], [[4bs4]], [[4bu3]], [[4bu5]], [[4bu6]], [[4bu7]], [[4bu8]], [[4bu9]], [[4bua]], [[4bud]], [[4bue]], [[4buf]], [[4bui]], [[4bus]], [[4but]], [[4buu]], [[4buv]], [[4buw]], [[4bux]], [[4buy]], [[4hyf]], [[4iue]], [[4j1z]], [[4j21]], [[4j22]], [[4j3l]], [[4j3m]], [[4m7b]], [[4pml]], [[4pnl]], [[4pnm]], [[4pnn]], [[4pnq]], [[4pnr]], [[4pns]], [[4pnt]], [[4tju]], [[4tjw]], [[4tjy]], [[4tk0]], [[4tk5]], [[4tkf]], [[4tkg]], [[4tki]], [[5aku]], [[5akw]], [[5al1]], [[5al2]], [[5al3]], [[5al4]], [[5al5]], [[4ufu]], [[4uhg]], [[4ui3]], [[4ui4]], [[4ui5]], [[4ui6]], [[4ui7]], [[4ui8]], [[4uvl]], [[4uvn]], [[4uvo]], [[4uvp]], [[4uvs]], [[4uvt]], [[4uvu]], [[4uvv]], [[4uvw]], [[4uvx]], [[4uvy]], [[4uvz]], [[4ux4]], [[4w5i]], [[5adq]], [[5adr]], [[5ads]], [[5adt]], [[5aeh]], [[5owt]], [[5ows]] - hTank 2 catalytic domain+ inhibitor<br />
-	**[[4hkk]], [[4hkn]], [[4hl5]], [[4hlf]], [[4hlg]], [[4hlh]], [[4hlk]], [[4hlm]], [[4hmh]], [[4kzl]], [[4kzq]], [[4kzu]], [[4l09]], [[4l0b]], [[4l0i]], [[4l0s]], [[4l0t]], [[4l0v]], [[4l10]], [[4l2f]], [[4l2g]], [[4l2k]], [[4l31]], [[4l32]], [[4l33]], [[4l34]], [[5c5p]], [[5c5q]], [[5c5r]], [[5dcz]], [[5fpf]], [[5fpg]] - hTank 2 catalytic and C terminal domains + inhibitor<br />	+	**[[4hkk]], [[4hkn]], [[4hl5]], [[4hlf]], [[4hlg]], [[4hlh]], [[4hlk]], [[4hlm]], [[4hmh]], [[4kzl]], [[4kzq]], [[4kzu]], [[4l09]], [[4l0b]], [[4l0i]], [[4l0s]], [[4l0t]], [[4l0v]], [[4l10]], [[4l2f]], [[4l2g]], [[4l2k]], [[4l31]], [[4l32]], [[4l33]], [[4l34]], [[5c5p]], [[5c5q]], [[5c5r]], [[5dcz]], [[5fpf]], [[5fpg]], [[5nxe]], [[5nwg]], [[5nwd]], [[5nwc]], [[5nwb]] [[5nvh]], [[5nvf]], [[5nve]], [[5nvc]], [[5nut]], [[5nt4]], [[5nt0]], [[5nsx]], [[5nsp]], [[5nob]], [[4ufy]] - hTank 2 catalytic and C terminal domains + inhibitor<br />
	}}		}}
	== References ==		== References ==
	<references/>		<references/>
	[[Category:Topic Page]]		[[Category:Topic Page]]